Mérieux Equity Partners is a prominent European investment firm based in Lyon, France, focusing on the healthcare and nutrition sectors. Established in 2009, the firm manages over €1.5 billion in assets through various funds dedicated to venture capital, growth, and buyout investments. It supports innovative medical solutions and health products, investing in companies ranging from early-stage startups to established leaders primarily in Europe and North America. The firm operates through multiple platforms, including a Venture Capital Platform that targets seed to Series B funding for diagnostic and therapeutic innovations, and a Growth/Buyout Platform that invests in more mature companies. Additionally, Mérieux Equity Partners has a Venture Studio, M2care, which co-develops early-stage HealthTech projects. The company partners closely with entrepreneurs and management teams, providing not only capital but also operational expertise and access to a broad network in the healthcare industry. With a dedicated team of professionals, Mérieux Equity Partners is committed to fostering growth and innovation in the healthcare and nutrition sectors.
We're tracking Merieux Equity Partners's market expansion
How Merieux Equity Partners's international expansion compares to its competitors
Merieux Equity PartnersYouBars show relative size across the companies compared.
Columns5| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
 Merieux Equity PartnersYou | 0 | 0 | — | 0 | 0 |
Marketing & Communication Specialist
View postingLyon, Auvergne-Rhône-Alpes, France · last yr.
No active campaigns
Sign up to track this company and get alerted the moment something changes.
Norgine acquires Theravia from Mérieux Equity Partners, strengthening its rare disease portfolio and European market position in specialty pharmaceuticals.
Ceva Animal Health restructures capital with renewed investor confidence, maintaining management control and independence while welcoming new investors to support global growth and innovation.
DeepUll raises €50M in Series C for rapid sepsis diagnosis. Led by Columbus, Panakès, Mérieux. UllCORE system detects pathogens in 1 hour.
Unlock verified emails & direct dials
Free · No credit card needed
Quick answers about Merieux Equity Partners's business, markets, and growth signals.
Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams full‑market visibility.
© 2026 Pubrio. All rights reserved.
